Nigel Grinter Email & Phone Number

Supplier of industrial gases with annual sales in excess of $10BB; Identified opportunities to develop improved manufacturing technologies for the biopharmaceutical industry, providing supporting scientific rationale, assessing technical feasibility and developing business case. For approved research programs, provided continuing technical and scientific oversight through R&D and commercialization phases.Three programs taken from inception to commercializationOne program to late-stage developmentFive programs in various stages of R&DFive patents filed

Provider of market information for the biotechnology and pharmaceutical industries; Contracted to write extensive Introduction and oversee production of an American Society for Microbiology publication: Advances in Large Scale BioManufacturing and Scale-up Production

Supplier of nucleic acid derivatives to the pharmaceutical/biotec industries ConsultantAdvised on the commercial potential of novel nucleic acid biochemistries.

Provider of tools for biological research to academic and commercial laboratories with revenues of $130M.; Established a directed evolution program for the identification and production of proteins with improved or novel properties useful for monitoring and quantifying biological processes.Developed new DNA cloning products to give the Company entry into a $50M market and boost other product sales.Initiated six significant new scientific projects using directed evolution for development of new products valued at $15M.Filed two patents.

Manufacturer of fine chemicals for the pharmaceutical industry with annual sales of $50M. Formerly a division of Monsanto Company, acquired; Discovered and developed biological processes for the manufacture of fine chemicals, human therapeutic agents and high-value food ingredients.Developed a proprietary generic process for pure isomers of amino acids for pharmaceutical manufacture using microbiological technologies, opening up a $50M market for the Company.Created a cost-effective process for manufacture of human growth hormone for patients with restricted growth with an estimated $10M market. Used advanced molecular biological approaches, developed the process in less than one year and prepared a patent application.Engineered bacteria to produce granulocyte colony stimulating factor (GCSF, used to aid recovery from cancer therapy) at levels suitable for commercial production and with market potential of $15M.Designed and developed a fermentation process for commercial manufacture of anthranilic acid

Manufacturer of high-potency artificial sweetener with sales of $400M.ConsultantAdvised on biological characterization and labeling requirements of product for sale in Europe Resolved issues relating to ownership of proprietary biological materials involved in the sale of NSC Technologies to Great Lakes Chemical Corporation, ensuring that the materials were properly documented, preserved and stored at the appropriate locations

Organized and taught a course in Molecular Biology, conducted an independent research program, organized final examinations and supervised Ph.D. students.Received research awards from Medical Research Council and Imperial Chemical Industries valued at $500,000.Devised and patented a system for the stable genetic modification of a wide range of industrially important bacteria.Publihed four academic papers in peer-reviewed journalsObtained three patents

B.Sc, Biological Sciences

Ph.D, Microbial Genetics